- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
Sturge Weber Syndrome (SWS) is a rare neurological disorder that affects the skin, eyes, and brain. It is caused by a mutation in the GNAQ gene. Symptoms of SWS include seizures, intellectual disability, and glaucoma. Treatment for SWS is typically focused on managing the symptoms, and may include medications, surgery, and lifestyle changes.
Drugs used to treat SWS are typically central nervous system (CNS) drugs, such as anticonvulsants, antipsychotics, and antiepileptics. These drugs are used to reduce the frequency and severity of seizures, as well as to improve cognitive functioning. Additionally, medications may be used to reduce the risk of glaucoma and other eye-related complications.
The market for SWS drugs is relatively small, due to the rarity of the disorder. However, there are a number of companies that are actively researching and developing treatments for SWS. These include AbbVie, Biogen, Eisai, and Novartis. Additionally, there are a number of smaller companies that are developing treatments for SWS, such as Aquestive Therapeutics, Neurogene, and Ovid Therapeutics. Show Less Read more